Media room

This collaboration involves clinicians, materials management and procurement teams, regulators, and industry experts, aiming to enhance patient care through clinically relevant and consistent evaluations. Mölnlycke Health Care has been a steadfast supporter of the WCCC from the start, working alongside other major wound care players on the project to improve patient outcomes. In a recent publication in the Wounds journal, the WCCC calls for a new era of wound dressing standards rooted in clinical relevance, biological validity, and consistency across product development and evaluation. Standardised, meaningful testing is not just about better comparisons—it is about fostering innovation. A clear, testing framework that is shared by all stakeholders: Helps clinicians make better-informed decisions based on consistent, evidence-based product evaluations, recognised by various stakeholders Progresses industry design and drives refinement of products with real-world performance in mind Helps researchers and regulators agree on functional dressing properties that align with clinical needs and ensure that pre-clinical testing appropriately reflects these needs  Dr. Sarah Griffiths Langbord, chair of the WCCC Gaps Dressing Standards Work Group, explains that the initiative has developed from an imminent need for standardisation. “Wound dressings are currently evaluated using various test methods, many of which are incompletely specified or insufficiently relevant to real-world wound care scenarios. This has resulted in individualised modifications by test users with no established best practices and no consistent baseline set of standardised tests for pre-clinical evaluations.” PhD Erik Nygren is Senior Scientist at Mölnlycke Health Care and one of several industry representatives on the work group. Nygren emphasises the importance of a unified framework to enhance the overall quality and clinical performance of wound dressing products. “During development, reliable, clinically relevant test methods are a prerequisite to achieve wound dressings with the right properties, which will meet true needs of clinicians and patients. By sharing knowledge and capabilities within the WCCC Gaps Work Group, we can accelerate progress and foster a unified community that benefits all stakeholders.” The WCCC urges the wound care community to get involved, as they need feedback from a wide range of stakeholders including clinicians, materials management and procurement teams, regulators, and industry experts. By identifying gaps in current standards, the WCCC can drive innovation in wound dressing development, shape research priorities, and highlight external funding opportunities to support pre-clinical research. Stakeholders can help the WCCC by taking a survey here: https://bit.ly/4cN7sIZ Read more about the WCCCs initiative to improve wound care standards here: https://www.hmpgloballearningnetwork.com/site/wounds/enhancing-patient-care-through-advanced-wound-dressing-standards-wound-care For more information, please contact:  [Contact card] Sofia Lindqvist

Barcelona, Spain. 27 March 2025. New study reports that switching patients with chronic wounds to the multi-layered, bordered silicone-coated foam dressing, Mepilex® Border Flex, alongside a clinician educational support programme, resulted in a significant reduction in the number of dressing changes being undertaken and a reduction in dressing-related costs.1  The study, sponsored by Mölnlycke Health Care, and conducted across primary care facilities in Seville, Spain was today presented as an e-poster at the 35th Conference of the European Wound Management Association (EWMA) 2025 in Barcelona, Spain by the principal investigator Dr Andres Roldan Valenzuela, Centro de Salud Mairena del Aljarafe – Cuidad Expo, Seville. The primary outcome of the study was a statistically significant reduction in the number of dressing changes undertaken, prior to and after the switch from a bordered foam dressing (baseline) to  Mepilex® Border Flex; results demonstrated the median number of dressing changes reduced during the study period, from three in a seven-day period to just one.1 Other reported outcomes included:1 32% wounds healed by the final visit 50% reduction in wound area in four weeks in 75% of patients Two thirds (68.7%) reduction in wound area from baseline to the final visit Reduced pain at dressing changes (pain severity scores of 3.1 - 3.3 at baseline associated with previously used dressings, compared to scores of 0.5 - 1.1 recorded with Mepilex® Border Flex at the final visit) 44% reduction in weekly dressing cost per patient (5.38€ less after the dressing switch) No dressing related adverse events Almost all (97%) of the clinicians rated the overall performance of Mepilex® Border Flex to be better than the previously used dressings, while 100% of patients rated Mepilex® Border Flex as ‘good’ to ‘very good’ in terms of overall satisfaction, compared to 65% for the previously used dressings. Dr Andres Roldan Valenzuela, principal investigator commented “The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.” For more information, please contact:  [Contact card] Sofia Lindqvist About the study design The study involved 37 adult patients, aged between 30 and 90+ years presenting with wounds that had not reduced in size by >40-50% in the previous month and had been managed with foam dressing (other than Mepilex® Border Flex), for a minimum of four weeks (baseline). Category 2 pressure ulcers (24.3%) and venous leg ulcers (18.9%) were the most common wound types. Patients in the study had Mepilex® Border Flex applied to their wounds for ≥4 weeks, in conjunction with standard of care.  

Gothenburg, Sweden. 28 January 2025. “This is a significant milestone in Mölnlycke’s commitment to halving Scope 1 and 2 greenhouse gas emissions by 2030” said Caterina Camerani, VP Sustainability at Mölnlycke. “It propels us towards our vision of building a sustainable healthcare manufacturing ecosystem.”   A major enabler in reaching the goal was signing two virtual Power Purchase Agreements (vPPAs) for the regions where the company has the highest manufacturing footprint. To cover electricity consumption for the sites in the European Union, Mölnlycke signed a long-term vPPA committing to purchasing renewable electricity generated in Mutkalampi, the largest wind farm in Finland. The three manufacturing plants in Malaysia will handle their renewable electricity needs through a similar vPPA from a newly established solar power plant in Bukit Kayu Hitam, Malaysia. In addition, Mölnlycke continues to invest in on-site generation of solar energy with manufacturing sites in Malaysia and the UK having completed the installation of rooftop solar panels and the installation on factories in Thailand ongoing. The remaining electricity consumption needs for the established manufacturing sites in Thailand, the UK and the US, as well as the newly established plant in the Kingdom of Saudi Arabia are met through Renewable Energy Certificates (RECs). As stated in the near-term goal validated by SBTi, Mölnlycke will continue active sourcing of renewable electricity through 2030.   For more information, please contact:  [Contact card] Sofia Lindqvist